Name (Synonyms) | Correlation | |
---|---|---|
D045169 | Severe Acute Respiratory Syndrome NIH | 0.06 |
D018352 | Coronavirus Infections NIH | 0.05 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
The purpose of this study is to assess the efficacy and safety of prazosin to prevent cytokine storm syndrome and severe complications in hospitalized patients with Coronavirus disease 2019 (COVID-19).
Description: Number of participants in each arm who expire.
Measure: Death Time: up to day 60Description: Number of participants in each arm who are hospitalized and requiring mechanical ventilation and/or high flow nasal cannula and/or ICU/CCU admission (or equivalent) and/or ECMO.
Measure: Hospitalized, requiring mechanical ventilation and/or high flow nasal cannula and/or ICU/CCU admission (or equivalent) and/or ECMO Time: up to day 60Description: Number of participants in each arm who are hospitalized and requiring supplemental oxygen, not requiring ICU/CCU level care (or interventions listed under Outcome 2).
Measure: Hospitalized, requiring supplemental oxygen, not requiring ICU/CCU level care (or interventions listed under Outcome 2) Time: up to day 60Description: Number of participants in each arm who develop grade 3 and 4 adverse events during the study period.
Measure: Cumulative incidence of grade 3 and 4 adverse events Time: up to day 60Description: Number of participants in each arm who develop serious adverse events during the study period.
Measure: Number of participants with serious adverse events Time: up to day 60Description: Number of participants in each arm who develop symptomatic hypotension (systolic blood pressure <90 mmHg) or hypotension requiring cessation of prazosin.
Measure: Incidence of symptomatic hypotension or hypotension requiring cessation of prazosin Time: up to day 60Description: Number of participants with laboratory abnormalities in peripheral blood (Lymphopenia, leukocytosis, anemia, thrombocytopenia, creatinine, AST/ALT, troponin I, pro-BNP, D-dimer, ferritin, interleukin (IL-6), soluble IL-2 receptor.
Measure: Number of participants with laboratory abnormalities in peripheral blood Time: up to day 60Description: Number of days with laboratory abnormalities in peripheral blood (Lymphopenia, leukocytosis, anemia, thrombocytopenia, creatinine, AST/ALT, troponin I, pro-BNP, D-dimer, ferritin, interleukin (IL-6), soluble IL-2 receptor.
Measure: Duration of laboratory abnormalities in peripheral blood Time: up to day 60Description: Number of participants with laboratory abnormalities in fractionated plasma catecholamines and plasma metanephrines.
Measure: Number of participants with laboratory abnormalities in plasma Time: up to day 60Description: Number of days with laboratory abnormalities in fractionated plasma catecholamines and plasma metanephrines.
Measure: Duration of laboratory abnormalities in plasma Time: up to day 60